Summary

Eligibility
for people ages 0-18 (full criteria)
Location
at UCLA
Dates
study started
study ends around
Principal Investigator
by Jonathan Santoro, MD (ucla)

Description

Summary

The IMPACT-Ready Study is a multi-site, international short-term prospective natural history study to develop new outcome measures, clinical endpoints, and biomarkers for autism and related neurodevelopmental conditions. The primary objective is to systematically document over time the behavioral, medical, neurophysiological, and genetic presentation of children with profound autism and related neurodevelopmental conditions. Participants will be initially separated into two cohorts: those with a confirmed diagnosis of a monogenic disorder associated with profound autism, including ARID1B, GRIN2B, RNU4-2, SCN2A, SLC6A1, or other genes of interest (Cohort 1), or those with likely profound or profound autism without a definitive genetic cause for their autism at the time of enrollment who use few or no words to communicate, with significant cognitive impairments (Cohort 2).

All participants will complete a baseline visit, and a subset of participants will complete either 6-month or annual follow-up visits based on the results of their genetic testing and their age.

After whole genome sequencing and Fragile X testing at the baseline visit, Cohort 2 will be split into 2 groups: Cohort 2a (those with a definitive genetic cause for autism not identified) and Cohort 2b (those with the presence of pathogenic or likely pathogenic variant(s) in a neurodevelopmental gene other than one of the targeted genes of interest AND those that do not meet the criteria for profound/likely profound autism following baseline assessment).

Official Title

Aligning Research to Impact Autism (ARIA) Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT)-Ready Study

Details

The ARIA IMPACT-Ready Study aims to better understand and measure how autism and related neurodevelopmental conditions develop and change over time. What we learn may help improve future research and treatments. Eligibility criteria is children ages 0-18 years who have a pathogenic or likely pathogenic variant in ARID1B, GRIN2B, RNU4-2, SCN2A, SLC6A1, or other genes of interest AND children ages 2-18 years who have likely profound or profound autism with no known genetic cause and use few or no words to communicate (are minimally verbal or non-verbal), with significant cognitive impairments. Participation lasts up to 2 years, and depending on the child's age, it involves 1 to 5 study visits. Each visit will last between 5-8 hours and may be split over 2 to 3 days, if needed. During the study, participants will:

  • Provide a blood or cheek swab sample for whole genome sequencing (WGS). The blood or cheek sample is also required from biological parents, if available.
  • Complete physical and neurological exams
  • Participate in play-based activities and surveys to better understand cognitive (IQ), behavioral, and developmental skills.
  • Participate in studies to examine biomarkers of brain function, such as electroencephalography and eye tracking
  • Wear a smartwatch, an EEG headband, and have a thin mat placed under their mattress to monitor their sleep at home for 3 nights.
  • Parents will also be asked questions about their child's family and medical history.

Families receive a detailed behavioral report, genetic testing results and $250 for each completed visit. Reasonable travel costs will be covered.

Keywords

Autism Spectrum Disorder, Neurodevelopmental Disorders, autism, natural history, profound autism, minimally verbal/nonverbal, ARID1B, GRIN2B, RNU4-2, SCN2A, SLC6A1, Clinical Trial Readiness, Coffin-Siris syndrome, GRIN2B-related neurodevelopmental disorder, ReNU syndrome, SCN2A-DEE, SLC6A1-Related Neurodevelopmental Disorder, Autistic Disorder

Eligibility

You can join if…

Open to people ages 0-18

  • For Cohort 1: age 0-18 years with clinical documentation of a genetically-defined disorder associated with profound autism, including a pathogenic/likely pathogenic variant in ARID1B, GRIN2B, RNU4-2, SCN2A, or SLC6A1.
  • For Cohort 2: ages 2-18 years with profound autism or likely profound autism, either without previous genetic testing or previous testing that was non-diagnostic.

You CAN'T join if...

  • For Cohort 1: Aged over 18 years at enrollment.
  • For Cohort 2: Age <2 or >18 years at enrollment
  • For Cohort 2: Participants with an established genetic diagnosis for their autism on the basis of a pathogenic variant (or variants) identified in a non-target neurodevelopmental gene.
  • Primary language other than English or Spanish.
  • Treatment with an investigational drug, biological agent, or device as part of another research study, within 30 days prior to study enrollment.
  • Previous treatments involving disease-modifying therapies, such as gene therapy, antisense oligonucleotide (ASO), or a repurposed drug.

Locations

  • Children's Hospital Los Angeles/University of California Los Angeles
    Los Angeles California 90027 United States
  • Seattle Children's Hospital/University of Washington
    Seattle Washington 98105 United States

Lead Scientist at University of California Health

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Coalition for Aligning Science
ID
NCT07931690
Study Type
Observational
Participants
Expecting 1250 study participants
Last Updated